Preprint2022
Computational Drug Design of Novel Small Molecule Inhibitors for Therapy in Pancreatic Ductal Adenocarcinoma
- Published
- 2 February 2022
- Citations
- 0
- Type
- Preprint
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Today, pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is one of the deadliest cancer types and remains largely unresolved. Through my research, I engineer a class of novel small molecule ligands to cure the disease by inhibiting its central carcinogenic pathway, taking the unique approach of applying the framework of targeted drug therapy and leveraging computer-aided techniques. … Excerpt only: this text is the publisher’s. Read it in full at the source.